Nanotechnology based drug delivery system(s) for the management of tuberculosis

Indian Journal of Experimental Biology

Volumn 44, Issue 5, 2006, Pages 357-366

  Pandey, Rajesh ^a   Khuller, G K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Alginate; Liposomes Nanoparticles; Poly lactide co glycolide; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ANIMAL; DRUG DELIVERY SYSTEM; GUINEA PIG; MOUSE; NANOTECHNOLOGY; REVIEW; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; GUINEA PIGS; MICE; NANOTECHNOLOGY; TUBERCULOSIS;

EID: 33646555437     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Hino M, Oda M, Yoshida A, Nakata K, Kohchi C, Nishizawa T, Inagawa H, Hori H, Makino K, Terada H & Soma G, Establishment of an in vitro model using NR8383 cells and Mycobacterium bovis calmette-guerin that mimics a chronic infection of Mycobacterium tuberculosis, In Vivo, 19 (2005), 821.
2. Williams B G, Granich R, Chauhan L S, Dharmshaktu N S & Dye C, The impact of HIV/AIDS on the control of tuberculosis in India, Proc Natl Acad Sci U S A, 102 (2005) 9619.
3. Dye C, Watt C J, Bleed D M, Hosseini S M & Raviglione M C, Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally, JAMA, 293 (2005) 2767.
4. Munoz-Elías E J, Timm J, Botha T, Chan W-T, Gomez J E & McKinney J D, Replication dynamics of Mycobacterium tuberculosis in chronically infected mice, Infect Immun 73 (2005) 546.
5. Weinstein E A, Yano T, Li L S, Avarbock D, Avarbock A, Helm D, McColm A A, Duncan K, Lonsdale J T & Rubin H, Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs, Proc Natl Acad Sci USA, 102 (2005) 4548.
6. Fine P E M, Variation in protection by BCG: implications of and for heterologous immunity, Lancet, 346 (1995) 1339.
7. Barry C E & Duncan K, Tuberculosis - strategies towards antiinfectives for a chronic disease. Drug Discov Today, 1 (2004) 491.
8. Pandey R & Khuller G K, Polymer based drug delivery systems for mycobacterial infections, Curr Drug Del, 1 (2004) 195.
9. Bala I, Hariharan S & Ravi Kumar M N V, PLGA nanoparticles in drug delivery: The state of the art, Crit Rev Ther Drug Carrier Syst, 21 (2004) 387.
10. Dutt M & Khuller G K. Poly (DL-lactide-co-glycolide) microparticles as carriers for antimycobacterial drug rifampicin. Indian J Exp Biol, 38 (2000) 887.
11. Dutt M & Khuller G K, Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glyoclide) microparticles as a therapeutic approach towards tuberculosis, Int J Antimicrob Agents, 17 (2001) 115.
12. Dutt M & Khuller G K, Chemotherapy of Mycobacterium tuberculosis infections in mice by combination of isoniazid and rifampicin drugs entrapped in poly (DL-lactide-co-glycolide) microparticles, J Antimicrob Chemother, 47 (2001) 829.
13. Dutt M & Khuller G K, Therapeutic efficacy of poly (DL-lactide-co-glycolide) encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice, Antimicrob Agents Chemother, 45 (2001) 363.
14. Gangadharam P R, Geeta N, Hsu Y Y & Wise D L, Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide, Int J Tuberc Lung Dis, 3 (1999) 515.
15. Ain Q, Sharma S, Garg S K & Khuller G K, Role of Poly (DL-lactide-co-glycolide) in development of sustained oral delivery system for antitubercular drug(s), Int J Pharm, 239 (2002) 34.
16. Ain Q, Sharma S & Khuller G K, Chemotherapeutic potential of orally administered poly (lactide-co-glycolide) microparticles containing isoniazid, rifampicin and pyrazinamide against experimental tuberculosis, Antimicrob Agents Chemother, 47 (2003) 3005.
17. Barrow E L W, Winchester G A, Staas J K, Quenelle D C & Barrow W W, Use of microsphere technology for sustained and targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages, Antimicrob Agents Chemother, 42 (1998) 2682.
18. Quenelle D C, Winchester G A, Stass J K, Barrow E L W & Barrow W W, Treatment of tuberculosis using a combination of sustained release rifampin loaded microspheres and oral dosing with isoniazid, Antimicrob Agents Chemother, 45 (2001) 1637.
19. Pandey R & Khuller G K, Antitubercular inhaled therapy: Opportunities, progress and challenges, J Antimicrob Chemother, 55 (2005) 430.
20. Suarez S, O' Hara P, Kazantseva M, Newcomer C E, Hopfer R, McMurray D N & Hickey A J, Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model, Pharm Res, 18 (2001) 1315.
21. Suarez S, O' Hara P, Kazantseva M, Newcomer C E, Hopfer R, McMurray D N & Hickey A J, Airways delivery of rifampicin microparticles for the treatment of tuberculosis, J Antimicrob Chemother, 48 (2001) 431.
22. Sharma R, Saxena D, Dwivedi A K & Misra A, Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis, Pharm Res, 18 (2001) 1405.
23. Tsapis N, Bennett D, O' Driscoll, Shea K, Lipp M M, Fu K, Clarke R W, Deaver D, Yamins D, Wright J, Peloquin C A, Weitz D A & Edwards D A, Direct lung delivery of paraaminosalicylic acid by aerosol particles, Tuberculosis (Edinb), 83 (2003) 379.
24. Moghimi S M, Hunter A C & Murray J C, Nanomedicine: current status and future prospects, FASEB J, 19 (2005) 311.
25. Emerich D F, Nanomedicine - prospective therapeutic and diagnostic applications, Expert Opin Biol Ther, 5 (2005) 1.
26. Youssef M, Fattal E, Alonso M J, Roblot-Treupel L, Sauzieres J, Tancrede C, Omnes A, Couvreur P & Andremont A, Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude mice, Antimicrob Agents Chemother, 32 (1988) 1204.
27. Umamaheshwari R B, Ramteke S & Jain N K, Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model, AAPS Pharm Sci Tech, 5 (2004) 32.
28. Venier-Julienne M C, Vouldoukis I, Monjour L & Benoit J P, In vitro study of the anti-leishmanial activity of biodegradable nanoparticles, J Drug Target, 3 (1995) 23.
29. Pandey R, Zahoor A, Sharma S & Khuller G K, Nanoencapsulation of azole antifungals: potential applications to improve oral drug bioavailability, Int J Pharm, 301 (2005) 268.
30. Mainardes R M & Evangelista R C, PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution, Int J Pharm, 290 (2005) 137.
31. Irache J M, Merodio M, Arnedo A, Camapanero M A, Mirshahi M & Espuelas S, Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem, 5 (2005) 293.
32. Florence A T & Hussain N, Transcytosis of nanoparticle and dendrimer delivery systems: Evolving vistas, Adv Drug Deliv Rev, 50 (2001) S69.
33. Pandey R, Ahmed Z, Sharma S & Khuller G K, Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis, Tuberculosis (Edinb), 83 (2003) 373.
34. Sharma A, Pandey R, Sharma S & Khuller G K, Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis, Int J Antimicrob Agents, 24 (2004) 599.
35. Pandey R, Sharma S & Khuller G K, Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs, Drug Deliv, (2005) (In Press).
36. Hodges G M, Carr E A, Hazzard R A & Carr K E, Uptake and translocation of microparticles in small intestine, Digest. Dis. Sci, 40 (1995) 967.
37. Sharma A, Sharma S & Khuller G K, Lectin functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis, J Antimicrob Chemother, 54 (2004), 761.
38. Johnson C M, Pandey R, Sharma S, Khuller G K, Basaraba R J, Ormes I M & Lenaerts A J, Oral therapy with poly (DL-lactide-co-glycolide) nanoparticle encapsulated antituberculosis drugs against Mycobacterium tuberculosis infected guinea pigs, Antimicrob Agents Chemother, 49 (2005) 4335.
39. Jacobs C & Muller R H, Production and characterisation of a budesonide nanosuspension for pulmonary administration. Pharm Res, 19 (2002) 189.
40. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller G K & Prasad B, Poly (DL-lactide-co-glycolide) nanoparticle based inhalable sustained drug delivery system for experimental tuberculosis, J Antimicrob Chemother, 52 (2003) 981.
41. Pandey R & Khuller GK, Subcutaneous nanoparticle based antitubercular chemotherapy in an experimental model, J Antimicrob Chemother, 54 (2004) 266.
42. Lewis D H, Controlled release of bioactive agents from lactide/glycolide polymers In: biodegradable polymers as drug delivery systems, M. Chasin and R. Langer, eds. (Marcel Dekker Inc, New York), 1990 1.
43. Anderson J M & Shive M S, Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv Rev, 28 (1997) 5.
44. Haris J, Laboratory synthesis of Polyethylene glycol derivatives, J Macromol Sci Rev Macromol Chem Phys, 25 (1985) 325.
45. Okada H, Once-month release injectable microspheres of leuprolide acetate, a superactive agonist of LH-RH, Proc Int Symp Contr Rel Bioact Mater, 16 (1989) 12.
46. Salem I I, Flasher D L & Duzgunes N, Liposome encapsulated antibiotics, Methods Enzymol, 391 (2005) 261.
47. Deol P & Khuller G K, Lung specific stealth liposomes; stability, biodistribution and toxicity of liposomal antitubercular drugs in mice, Biochim Biophys Acta, 1334 (1997) 161.
48. Deol P, Khuller G K & Joshi K, Therapeutic efficacy of isoniazid and rifampin encapsulated in lung specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice, Antimicrob Agents Chemother, 41 (1997) 1211.
49. Labana S, Pandey R, Sharma S & Khuller G K, Chemotherapeutic activity of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes against murine tuberculosis, Int J Antimicrob Agents, 20 (2002) 301.
50. Pandey R, Sharma S & Khuller G K, Liposomes based antitubercular drug therapy in a guinea pig model of tuberculosis, Int J Antimicrob Agents 23 (2004) 414.
51. Pandey R, Sharma S & Khuller G K, Nebulization of liposome encapsulated antitubercular drugs in guinea pigs, Int J Antimicrob Agents, 24 (2004) 93.
52. Justo O R & Moraes A M, Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation, Drug Deliv, 10 (2003) 201.
53. Kurunov I N, Ursov I G, Krasnov V A, Petrenko T I, Iakovchenko N N, Svistelnik A V & Filimonov P A, Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis, Probl tuberk, 1 (1995) 38.
54. Vyas S P, Kannan M E, Jain S, Mishra V & Singh P, Design of liposomal aerosol for improved delivery of rifampicin to alveolar macrophages, Int J Pharm, 269 (2004) 37.
55. Thomas D A, Myers M A, Wichert B, Shcreier H, Gonzalez-Rothi R J, Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers, Chest, 99 (1991) 1268.
56. Rao G C, Kumar M S, Mathivanan N & Rao M E, Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems, Pharmazie, 59 (2004) 5.
57. Pandey R & Khuller G K, Solid lipid particle based inhalable sustained drug delivery system against experimental tuberculosis, Tuberculosis (Edinb), 85 (2005) 227.
58. Pandey R, Sharma S & Khuller G K, Oral solid lipid nanoparticle based antitubercular chemotherapy, Tuberculosis (Edinb), 85 (2005) 415.
59. Tonnesen H H & Karlsen J, Alginate in drug delivery systems, Drug Dev Ind Pharm, 28 (2002) 621.
60. Pandey R & Khuller G K, Alginate as a drug delivery carrier, in Handbook of Carbohydrate Engineering, edited by K J Yarema, (Taylor and Francis Group, CRC Press, Boca Raton, Florida), (2005), 799.
61. Ain Q, Sharma S, Khuller G K & Garg S K, Alginate based oral drug delivery system for tuberculosis: Pharmacokinetics and therapeutic effects, J Antimicrob Chemother, 51 (2003) 931.
62. Pandey R & Khuller G K, Chemotherapeutic potential of alginate chitosan microspheres as antitubercular drug carriers, J Antimicrob Chemother, 53 (2004) 635.
63. Zahoor A, Sharma S & Khuller G K, Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis, Int J Antimicrob Agents, 26 (2005) 298.